By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BlackThorn Therapeutics 

JLABS
329 Oyster Point Boulevard, 3rd Floor
South San Francisco  California  94080  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments. BlackThorn is building a robust pipeline of first- and best-in-class treatments, and is redefining the industry approach to drug discovery and development through its INFORMâ„¢ platform, which links brain physiology and its relationship to behavior. With its network of collaborations with leading academic investigators, BlackThorn is developing and deploying a set of technologies that will enable focused, rapid, resource-efficient translational studies for drug development. The company is headquartered in South San Francisco, California.

YEAR FOUNDED:

2015

LEADERSHIP:

Executive Chairman: Mark Corrigan, M.D.

CSO: Bill Martin, Ph.D.

CMO: Annette Madrid, M.D.

Vice President, Operations and Corporate Development: Scott Forrest, Ph.D.

JOBS:

Please click here for BlackThorn's job opportunities.


PIPELINE:

Please click here for BlackThorn's pipeline.


Key Statistics


Email: info@blackthornrx.com
Ownership: Private

Web Site: BlackThorn Therapeutics
Employees:
Symbol: 
 









Company News
BlackThorn Therapeutics Names Matthew K. Fust To Board Of Directors 8/1/2017 12:25:51 PM
BlackThorn Therapeutics Enrolls First Patient In Phase IIa Study Of Lead Compound, BTRX-246040, In Major Depressive Disorder 7/24/2017 8:06:20 AM
BlackThorn Therapeutics To Receive Up To $8 Million In NIH Blueprint Neurotherapeutics Network Funding To Advance Kappa Opioid Receptor (KOR) Antagonist Program 6/20/2017 10:09:07 AM
BlackThorn Therapeutics Announces Innovative Clinical Collaboration Agreement With Mindstrong Health 6/7/2017 7:18:12 AM
BlackThorn Therapeutics Announces Results Of Preclinical Study Of BTRX-335140, Demonstrating Therapeutic Potential In Modulating Brain Circuits Commonly Dysregulated In Neurobehavioral Disorders 4/6/2017 7:58:22 AM
BlackThorn Therapeutics Names Biotech Industry Veteran Gregory Vontz As Chief Executive Officer 2/7/2017 8:20:39 AM
Bay Area Startup BlackThorn Therapeutics Nabs Another $14 Million, Bringing Its Series A Total to $54 Million 1/5/2017 9:13:02 AM
Bay Area's BlackThorn Therapeutics Comes Out of Stealth Mode With $40 Million to Push New Neuroscience Drugs Into Trials 10/20/2016 7:20:58 AM
//-->